Given our patient's multiple comorbidities but preserved performance status and functional independence, and following comprehensive clinical assessment principles recommended for elderly cancer patients, first-line palliative treatment with a CDK4/6 inhibitor in combination with endocrine therapy was initiated, as they are safe and effective drugs for the elderly population [17-19]. The gene discussed is CDK4; the disease is cancer.